Boron Neutron Capture Therapy for Malignant Brain Tumors
Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy tra...
Saved in:
| Published in | Neurologia medico-chirurgica Vol. 56; no. 7; pp. 361 - 371 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Japan Neurosurgical Society
01.01.2016
THE JAPAN NEUROSURGICAL SOCIETY |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting. |
|---|---|
| AbstractList | Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting. [Abstract] Boron neutron capture therapy [BNCT] is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting. |
| Author | MIYATAKE, Shin-Ichi ONO, Koji KUROIWA, Toshihiko KAWABATA, Shinji HIRAMATSU, Ryo KONDO, Natsuko SUZUKI, Minoru |
| Author_xml | – sequence: 1 fullname: KUROIWA, Toshihiko organization: Department of Neurosurgery, Osaka Medical College – sequence: 1 fullname: ONO, Koji organization: Particle Radiation Oncology Research Center, Kyoto University Research, Reactor Institute – sequence: 1 fullname: MIYATAKE, Shin-Ichi organization: Department of Neurosurgery, Osaka Medical College – sequence: 1 fullname: SUZUKI, Minoru organization: Particle Radiation Oncology Research Center, Kyoto University Research, Reactor Institute – sequence: 1 fullname: KONDO, Natsuko organization: Particle Radiation Oncology Research Center, Kyoto University Research, Reactor Institute – sequence: 1 fullname: KAWABATA, Shinji organization: Department of Neurosurgery, Osaka Medical College – sequence: 1 fullname: HIRAMATSU, Ryo organization: Department of Neurosurgery, Osaka Medical College |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27250576$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UU1vEzEQtVARDaF3TmiPXDb4c7x7QaIR_ZAKXMLZ8jrexNWuHezdSv332KSNCgdkaWasmffeaN5bdOaDtwi9J3hFiYRPfjSrqFcUE1Fj2spXaEEYb-smf87QAnOJ64ZgcY4uUnIdxpQ3nDXyDTqnkgosJCxQcxli8NV3O08lr_VhmqOtNnsb9eGx6kOsvunB7bz2U3UZtfPVZh5DTO_Q614PyV485SX6efV1s76p735c366_3NVGtmSqO7AEdN_1YAg1sm8BSkkM6xnp6RbaDvSWCwwdSA0tBca2xlogTUd6ydkSfT7yHuZutLnlp6gHdYhu1PFRBe3U3x3v9moXHhRvuRBtIfj4RBDDr9mmSY0uGTsM2tswJ0UaJhlnOL8l-vBS6yTyfK48AMcBE0NK0fbKuElPLhRpNyiCVbFGZWtU1KpYo4o1GYj_AT5z_wdyfYTkTZzRQ_CD81bdhzn6fHBltsTb7FWBgMJYAJY5UYUZkBwkodByEIXp6sh0nya9sydpHSdnBvtHWoCSJbxc4TRg9joq69lvhcDCEA |
| CitedBy_id | crossref_primary_10_1016_j_apradiso_2023_110792 crossref_primary_10_3390_cancers15143626 crossref_primary_10_3389_fncel_2024_1440559 crossref_primary_10_1016_j_jconrel_2021_02_021 crossref_primary_10_1016_j_jconrel_2021_08_044 crossref_primary_10_1039_D0PY01392G crossref_primary_10_2217_nnm_2020_0401 crossref_primary_10_21294_1814_4861_2021_20_2_77_84 crossref_primary_10_1007_s00411_019_00796_z crossref_primary_10_1002_adma_201700850 crossref_primary_10_3390_biology10111124 crossref_primary_10_1016_j_bbrc_2016_12_176 crossref_primary_10_1038_s41598_018_34643_w crossref_primary_10_3390_pharmaceutics14040761 crossref_primary_10_1007_s11172_020_2763_1 crossref_primary_10_1021_acs_molpharmaceut_1c00810 crossref_primary_10_3390_vetsci10040274 crossref_primary_10_1002_adhm_202001632 crossref_primary_10_1515_mr_2023_0013 crossref_primary_10_3390_biology10040334 crossref_primary_10_3390_life12081264 crossref_primary_10_1016_j_adro_2025_101736 crossref_primary_10_3390_ijms242317088 crossref_primary_10_1246_cl_161137 crossref_primary_10_1002_cmdc_201800793 crossref_primary_10_1002_med_22093 crossref_primary_10_1016_j_ccr_2020_213753 crossref_primary_10_1080_03639045_2022_2032132 crossref_primary_10_1360_TB_2021_0907 crossref_primary_10_1002_osi2_1014 crossref_primary_10_2217_nnm_2022_0330 crossref_primary_10_1007_s12149_018_1268_6 crossref_primary_10_3390_inorganics7050059 crossref_primary_10_3390_pharmaceutics15122663 crossref_primary_10_3390_life12122071 crossref_primary_10_1007_s10337_020_03995_9 crossref_primary_10_1093_jrr_rrx080 crossref_primary_10_1021_acsami_0c15251 crossref_primary_10_1080_01480545_2018_1504057 crossref_primary_10_1111_iju_14855 crossref_primary_10_3390_biology11010138 crossref_primary_10_3390_molecules24040794 crossref_primary_10_1016_j_nima_2018_05_025 crossref_primary_10_3390_cells11244029 crossref_primary_10_1007_s12149_019_01347_8 crossref_primary_10_1016_j_jconrel_2020_11_001 crossref_primary_10_3390_cancers12102860 crossref_primary_10_1007_s00411_018_0765_2 crossref_primary_10_1021_acsami_8b14682 crossref_primary_10_1016_j_apradiso_2024_111184 crossref_primary_10_1002_adfm_202303366 crossref_primary_10_1016_j_apradiso_2020_109105 crossref_primary_10_3390_cells10123398 crossref_primary_10_1007_s11060_020_03586_6 crossref_primary_10_1259_bjr_20200311 crossref_primary_10_1002_chem_201803178 crossref_primary_10_1017_erm_2022_6 crossref_primary_10_1088_1748_0221_12_03_C03038 crossref_primary_10_1248_cpb_c19_00971 crossref_primary_10_3390_cells10112883 crossref_primary_10_1111_1759_7714_13232 crossref_primary_10_3389_fonc_2021_601820 crossref_primary_10_1016_j_nimb_2021_09_014 crossref_primary_10_2176_nmccrj_cr_2019_0228 crossref_primary_10_1002_mp_17693 crossref_primary_10_1038_s41598_023_37296_6 crossref_primary_10_1007_s11172_017_1936_z crossref_primary_10_3390_ijms24119393 crossref_primary_10_3390_pharmaceutics13091490 crossref_primary_10_7887_jcns_32_741 crossref_primary_10_3389_fonc_2022_925671 crossref_primary_10_1007_s10895_020_02637_5 crossref_primary_10_1093_jrr_rrac030 crossref_primary_10_1016_j_nima_2024_169260 crossref_primary_10_1016_j_inoche_2023_111698 crossref_primary_10_1016_j_biomaterials_2018_03_038 crossref_primary_10_3233_JNR_210012 crossref_primary_10_7887_jcns_33_96 crossref_primary_10_3390_cells9051277 crossref_primary_10_1667_RR15249_1 crossref_primary_10_3390_cancers12051334 crossref_primary_10_3390_cells10113225 crossref_primary_10_1007_s12094_018_1831_6 crossref_primary_10_1002_ejoc_202000396 |
| Cites_doi | 10.1007/BF02699929 10.1098/rspa.1932.0112 10.1016/j.apradiso.2009.03.030 10.1093/brain/114.4.1609 10.1016/j.radonc.2009.02.009 10.3171/2013.5.JNS122204 10.1158/1078-0432.CCR-06-0141 10.1007/BF02699937 10.1097/CCO.0b013e328356364d 10.1007/s11060-008-9699-x 10.1007/s11060-009-9945-x 10.1016/j.apradiso.2011.03.020 10.1002/hed.20418 10.1269/jrr.08043 10.3171/jns.2006.105.6.898 10.3171/jns.2005.103.6.1000 10.1158/1078-0432.CCR-05-0035 10.1021/cr941195u 10.1007/BF02699938 10.1016/j.apradiso.2009.03.103 10.1002/jps.24317 10.1021/bc950077q 10.1016/j.biomaterials.2013.12.055 10.1021/bc0501350 10.1016/j.radonc.2006.04.015 10.1007/s11060-008-9621-6 10.1016/j.ijrobp.2009.12.061 10.2174/138955707780059808 10.1093/jnci/85.9.704 10.1007/s11060-008-9522-8 10.1227/01.neu.0000279727.90650.24 10.3171/jns.1997.86.5.0793 10.1021/jm900763b 10.1097/00005072-197204000-00005 10.1023/A:1005781517624 10.1158/1535-7163.MCT-05-0161 10.1158/1078-0432.CCR-07-1968 10.1016/j.ijrobp.2010.09.057 10.1093/neuonc/nov227.04 10.1186/1748-717X-9-6 10.2174/187152006776119135 10.1093/neuonc/not020 10.1158/1078-0432.CCR-06-2399 10.1200/JCO.2006.08.1661 10.1007/s11060-010-0333-3 10.1016/S0360-3016(96)00241-6 10.1016/0090-3019(86)90233-8 10.1016/j.apradiso.2011.03.014 10.1016/j.apradiso.2009.03.018 10.1016/0360-3016(95)02180-9 10.1016/j.apradiso.2004.05.059 10.1007/BF02699939 10.1016/j.apradiso.2009.03.024 10.1023/B:NEON.0000003751.67562.8e 10.1002/lsm.21026 10.1016/j.apradiso.2014.01.011 |
| ContentType | Journal Article |
| Copyright | 2016 by The Japan Neurosurgical Society 2016 The Japan Neurosurgical Society 2016 |
| Copyright_xml | – notice: 2016 by The Japan Neurosurgical Society – notice: 2016 The Japan Neurosurgical Society 2016 |
| CorporateAuthor | Department of Neurosurgery Reactor Institute Kyoto University Research Osaka Medical College Particle Radiation Oncology Research Center Cancer Center |
| CorporateAuthor_xml | – name: Osaka Medical College – name: Department of Neurosurgery – name: Kyoto University Research – name: Particle Radiation Oncology Research Center – name: Cancer Center – name: Reactor Institute |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 5PM |
| DOI | 10.2176/nmc.ra.2015-0297 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1349-8029 |
| EndPage | 371 |
| ExternalDocumentID | PMC4945594 27250576 10_2176_nmc_ra_2015_0297 cd1neure_2016_005607_002_0361_03712694657 article_nmc_56_7_56_ra_2015_0297_article_char_en |
| Genre | Journal Article Review |
| GroupedDBID | --- .55 .GJ 123 29N 2WC 3O- 53G 7.U ACPRK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BKOMP CS3 DIK DU5 E3Z F5P GROUPED_DOAJ GX1 HYE JMI JSF JSH KQ8 MOJWN OK1 OVT P6G PGMZT RJT RNS RPM RZJ TKC TR2 X7J X7M AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 5PM |
| ID | FETCH-LOGICAL-c791t-b6e16afbf6c12c7f966f6c11c3f31f2d69b6ad4506b67a692633dcee618b1f743 |
| ISSN | 0470-8105 |
| IngestDate | Thu Aug 21 14:16:44 EDT 2025 Fri Jul 11 04:39:05 EDT 2025 Thu Jan 02 22:45:08 EST 2025 Tue Jul 01 00:55:01 EDT 2025 Thu Apr 24 23:10:41 EDT 2025 Thu Jul 10 16:15:02 EDT 2025 Wed Sep 03 06:28:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-nd/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c791t-b6e16afbf6c12c7f966f6c11c3f31f2d69b6ad4506b67a692633dcee618b1f743 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 There is no conflict of interest to disclose for any of the authors. Conflicts of Interest Disclosure |
| OpenAccessLink | http://dx.doi.org/10.2176/nmc.ra.2015-0297 |
| PMID | 27250576 |
| PQID | 1837343030 |
| PQPubID | 23462 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4945594 proquest_miscellaneous_1837343030 pubmed_primary_27250576 crossref_citationtrail_10_2176_nmc_ra_2015_0297 crossref_primary_10_2176_nmc_ra_2015_0297 medicalonline_journals_cd1neure_2016_005607_002_0361_03712694657 jstage_primary_article_nmc_56_7_56_ra_2015_0297_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-01 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Neurologia medico-chirurgica |
| PublicationTitleAlternate | Neurol. Med. Chir.(Tokyo) |
| PublicationYear | 2016 |
| Publisher | The Japan Neurosurgical Society THE JAPAN NEUROSURGICAL SOCIETY |
| Publisher_xml | – name: The Japan Neurosurgical Society – name: THE JAPAN NEUROSURGICAL SOCIETY |
| References | 12) Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG: The chemistry of neutron capture therapy. Chem Rev 98: 1515–1562, 1998 54) Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM: Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4: 1423–1429, 2005 10) Farr LE, Sweet WH, Locksley HB, Robertson JS: Neutron capture therapy of gliomas using boron. Trans Am Neurol Assoc 13: 110–113, 1954 14) Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res 4: 1825–1832, 1998 36) Yamamoto T, Nakai K, Kageji T, Kumada H, Endo K, Matsuda M, Shibata Y, Matsumura A: Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 91: 80–84, 2009 51) Hiramatsu R, Kawabata S, Miyatake S, Kuroiwa T, Easson MW, Vicente MG: Application of a novel boronated porphyrin (H2OCP) as a dual sensitizer for both PDT and BNCT. Lasers Surg Med 43: 52–58, 2011 57) Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ: Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 14: 883–891, 2008 16) Takahashi Y, Imahori Y, Mineura K: Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas. Clin Cancer Res 9: 5888–5895, 2003 9) Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, Imahori Y, Suzuki M, Sakrai Y, Sumi T, Iwai S, Nakazawa M, Murata I, Miyamaru H, Ono K: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 67: S37–S42, 2009 44) Bregadze VI, Sivaev IB, Lobanova IA, Titeev RA, Brittal DI, Grin MA, Mironov AF: Conjugates of boron clusters with derivatives of natural chlorin and bacteriochlorin. Appl Radiat Isot 67: S101–S104, 2009 45) Altieri S, Balzi M, Bortolussi S, Bruschi P, Ciani L, Clerici AM, Faraoni P, Ferrari C, Gadan MA, Panza L, Pietrangeli D, Ricciardi G, Ristori S: Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem 52: 7829–7835, 2009 5) Slatkin DN: A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain 114 (Pt 4):1609–1629, 1991 26) Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI: A prospective multicenter single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neuro-Oncology Practice [in press] 56) Wu G, Yang W, Barth RF, Kawabata S, Swindall M, Bandyopadhyaya AK, Tjarks W, Khorsandi B, Blue TE, Ferketich AK, Yang M, Christoforidis GA, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA: Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 13: 1260–1268, 2007 6) Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, Ono K, Harada T: First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck 28: 850–855, 2006 8) Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y: Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61: 1069–1073, 2004 29) Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704–710, 1993 40) Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K: Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg 105: 898–903, 2006 61) Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T: Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39: 325–333, 1998 28) Laramore GE, Spence AM: Boron neutron capture therapy (BNCT) for high-grade gliomas of the brain: a cautionary note. Int J Radiat Oncol Biol Phys 36: 241–246, 1996 1) Chadwick J: The existence of a neutron. Proc R Soc London A 136: 692–708, 1932 42) Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Mitsumoto T, Fujita K, Kashino G, Kinashi Y, Liu Y, Takada M, Ono K, Maruhashi A: Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Appl Radiat Isot 69: 1642–1645, 2011 55) Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ: Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12: 3792–3802, 2006 4) Barth RF, Coderre JA, Vicente MG, Blue TE: Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11: 3987–4002, 2005 3) Barth RF: A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 62: 1–5, 2003 46) Li T, Hamdi J, Hawthorne MF: Unilamellar liposomes with enhanced boron content. Bioconjug Chem 17: 15–20, 2006 19) Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S: Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg 119: 837–844, 2013 18) Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, Kuroiwa T, Tsuji M, Imahori Y, Kirihata M, Sakurai Y, Masunaga S, Nagata K, Maruhashi A, Ono K: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 103: 1000–1009, 2005 33) Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vähätalo J, Kortesniemi M, Kotiluoto P, Serén T, Karila J, Brander A, Järviluoma E, Ryynänen P, Paetau A, Ruokonen I, Minn H, Tenhunen M, Jääskeläinen J, Färkkilä M, Savolainen S: Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol 62: 123–134, 2003 31) Diaz AZ: Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view. J Neurooncol 62: 101–109, 2003 48) Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S: Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 87: 287–294, 2008 15) Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res 4: 1833–1841, 1998 37) Jääskeläinen J, Haltia M, Servo A: Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25: 233–242, 1986 17) Kawabata S, Miyatake S, Kajimoto Y, Kuroda Y, Kuroiwa T, Imahori Y, Kirihata M, Sakurai Y, Kobayashi T, Ono K: The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. J Neurooncol 65: 159–165, 2003 59) Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K: Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 67: S328–S331, 2009 24) Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, Ono K: Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. Neuro-oncology 15: 650–655, 2013 22) Furuse M, Kawabata S, Kuroiwa T, Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 102: 471–475, 2011 32) Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzén L, Blomquist E, Westlin JE, Bergenheim AT; Swedish Brain Tumour Study Group: Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 88: 183–191, 2008 2) Locher GL: Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther 36: 1–13, 1936 52) Hiramatsu R, Kawabata S, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake S, Kuroiwa T, Hao E, Vicente MG: Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy. J Pharm Sci 104: 962–970, 2015 30) Busse PM, Harling OK, Palmer MR, Kiger WS, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu XQ, Zamenhof RG: A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 62: 111–121, 2003 35) Kawabata S, Miyatake S, Hiramatsu R, Hirota Y, Miyata S, Takekita Y, Kuroiwa T, Kirihata M, Sakurai Y, Maruhashi A, Ono K: Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly 44 45 46 47 48 49 50 51 52 53 10 54 11 55 12 56 13 57 14 58 15 59 16 17 18 19 1 2 3 4 5 6 7 8 9 60 61 62 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
| References_xml | – reference: 16) Takahashi Y, Imahori Y, Mineura K: Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas. Clin Cancer Res 9: 5888–5895, 2003 – reference: 31) Diaz AZ: Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view. J Neurooncol 62: 101–109, 2003 – reference: 58) Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ: Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J Neurooncol 95: 355–365, 2009 – reference: 49) Ito Y, Kimura Y, Shimahara T, Ariyoshi Y, Shimahara M, Miyatake S, Kawabata S, Kasaoka S, Ono K: Disposition of TF-PEG-liposome-BSH in tumor-bearing mice. Appl Radiat Isot 67: S109–S110, 2009 – reference: 33) Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vähätalo J, Kortesniemi M, Kotiluoto P, Serén T, Karila J, Brander A, Järviluoma E, Ryynänen P, Paetau A, Ruokonen I, Minn H, Tenhunen M, Jääskeläinen J, Färkkilä M, Savolainen S: Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol 62: 123–134, 2003 – reference: 40) Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K: Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg 105: 898–903, 2006 – reference: 36) Yamamoto T, Nakai K, Kageji T, Kumada H, Endo K, Matsuda M, Shibata Y, Matsumura A: Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 91: 80–84, 2009 – reference: 9) Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, Imahori Y, Suzuki M, Sakrai Y, Sumi T, Iwai S, Nakazawa M, Murata I, Miyamaru H, Ono K: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 67: S37–S42, 2009 – reference: 43) Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Mitsumoto T, Kinashi Y, Kondo N, Narabayashi M, Nakagawa Y, Watanabe T, Fujimoto N, Maruhashi A, Ono K: Evaluation of thermal neutron irradiation field using a cyclotron-based neutron source for alpha autoradiography. Appl Radiat Isot 88: 153–156, 2014 – reference: 62) Miyashita M, Miyatake S, Imahori Y, Yokoyama K, Kawabata S, Kajimoto Y, Shibata MA, Otsuki Y, Kirihata M, Ono K, Kuroiwa T: Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol 89: 239–246, 2008 – reference: 48) Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S: Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 87: 287–294, 2008 – reference: 19) Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S: Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg 119: 837–844, 2013 – reference: 3) Barth RF: A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 62: 1–5, 2003 – reference: 8) Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y: Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61: 1069–1073, 2004 – reference: 11) Asbury AK, Ojemann RG, Nielsen SL, Sweet WH: Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 31: 278–303, 1972 – reference: 24) Miyatake S, Furuse M, Kawabata S, Maruyama T, Kumabe T, Kuroiwa T, Ono K: Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases. Neuro-oncology 15: 650–655, 2013 – reference: 37) Jääskeläinen J, Haltia M, Servo A: Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25: 233–242, 1986 – reference: 46) Li T, Hamdi J, Hawthorne MF: Unilamellar liposomes with enhanced boron content. Bioconjug Chem 17: 15–20, 2006 – reference: 22) Furuse M, Kawabata S, Kuroiwa T, Miyatake S: Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 102: 471–475, 2011 – reference: 10) Farr LE, Sweet WH, Locksley HB, Robertson JS: Neutron capture therapy of gliomas using boron. Trans Am Neurol Assoc 13: 110–113, 1954 – reference: 57) Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ: Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 14: 883–891, 2008 – reference: 15) Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res 4: 1833–1841, 1998 – reference: 28) Laramore GE, Spence AM: Boron neutron capture therapy (BNCT) for high-grade gliomas of the brain: a cautionary note. Int J Radiat Oncol Biol Phys 36: 241–246, 1996 – reference: 4) Barth RF, Coderre JA, Vicente MG, Blue TE: Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11: 3987–4002, 2005 – reference: 23) Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79: 1487–1495, 2011 – reference: 2) Locher GL: Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther 36: 1–13, 1936 – reference: 1) Chadwick J: The existence of a neutron. Proc R Soc London A 136: 692–708, 1932 – reference: 35) Kawabata S, Miyatake S, Hiramatsu R, Hirota Y, Miyata S, Takekita Y, Kuroiwa T, Kirihata M, Sakurai Y, Maruhashi A, Ono K: Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme—study design and current status report. Appl Radiat Isot 69: 1796–1799, 2011 – reference: 29) Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704–710, 1993 – reference: 13) Ono K, Masunaga SI, Kinashi Y, Takagaki M, Akaboshi M, Kobayashi T, Akuta K: Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys 34: 1081–1086, 1996 – reference: 47) Crossley EL, Ziolkowski EJ, Coderre JA, Rendina LM: Boronated DNA-binding compounds as potential agents for boron neutron capture therapy. Mini Rev Med Chem 7: 303–313, 2007 – reference: 53) Capala J, Barth RF, Bendayan M, Lauzon M, Adams DM, Soloway AH, Fenstermaker RA, Carlsson J: Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem 7: 7–15, 1996 – reference: 26) Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI: A prospective multicenter single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neuro-Oncology Practice [in press] – reference: 27) Nakagawa Y, Hatanaka H: Boron neutron capture therapy. Clinical brain tumor studies. J Neurooncol 33: 105–115, 1997 – reference: 54) Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM: Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4: 1423–1429, 2005 – reference: 56) Wu G, Yang W, Barth RF, Kawabata S, Swindall M, Bandyopadhyaya AK, Tjarks W, Khorsandi B, Blue TE, Ferketich AK, Yang M, Christoforidis GA, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA: Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 13: 1260–1268, 2007 – reference: 52) Hiramatsu R, Kawabata S, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake S, Kuroiwa T, Hao E, Vicente MG: Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy. J Pharm Sci 104: 962–970, 2015 – reference: 12) Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG: The chemistry of neutron capture therapy. Chem Rev 98: 1515–1562, 1998 – reference: 20) Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, Kumada H, Suzuki M, Maruhashi A, Kirihata M, Ono K: Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 91: 199–206, 2009 – reference: 34) Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K, Miyata S, Nonoguchi N, Michiue H, Takahashi M, Inomata T, Imahori Y, Kirihata M, Sakurai Y, Maruhashi A, Kumada H, Ono K: Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res 50: 51–60, 2009 – reference: 30) Busse PM, Harling OK, Palmer MR, Kiger WS, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu XQ, Zamenhof RG: A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 62: 111–121, 2003 – reference: 5) Slatkin DN: A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain 114 (Pt 4):1609–1629, 1991 – reference: 44) Bregadze VI, Sivaev IB, Lobanova IA, Titeev RA, Brittal DI, Grin MA, Mironov AF: Conjugates of boron clusters with derivatives of natural chlorin and bacteriochlorin. Appl Radiat Isot 67: S101–S104, 2009 – reference: 42) Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Mitsumoto T, Fujita K, Kashino G, Kinashi Y, Liu Y, Takada M, Ono K, Maruhashi A: Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Appl Radiat Isot 69: 1642–1645, 2011 – reference: 21) Carson KA, Grossman SA, Fisher JD, Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25: 2601–2606, 2007 – reference: 38) Palma L, Celli P, Franco C, Cervoni L, Cantore G: Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 86: 793–800, 1997 – reference: 55) Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ: Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12: 3792–3802, 2006 – reference: 59) Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K: Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 67: S328–S331, 2009 – reference: 50) Renner MW, Miura M, Easson MW, Vicente MG: Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy. Anticancer Agents Med Chem 6: 145–157, 2006 – reference: 39) Chamberlain MC: The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Curr Opin Oncol 24: 666–671, 2012 – reference: 6) Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, Ono K, Harada T: First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck 28: 850–855, 2006 – reference: 41) Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K: Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 61: 82–90; discussion 90–91, 2007 – reference: 61) Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T: Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39: 325–333, 1998 – reference: 17) Kawabata S, Miyatake S, Kajimoto Y, Kuroda Y, Kuroiwa T, Imahori Y, Kirihata M, Sakurai Y, Kobayashi T, Ono K: The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. J Neurooncol 65: 159–165, 2003 – reference: 32) Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzén L, Blomquist E, Westlin JE, Bergenheim AT; Swedish Brain Tumour Study Group: Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 88: 183–191, 2008 – reference: 18) Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, Kuroiwa T, Tsuji M, Imahori Y, Kirihata M, Sakurai Y, Masunaga S, Nagata K, Maruhashi A, Ono K: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 103: 1000–1009, 2005 – reference: 45) Altieri S, Balzi M, Bortolussi S, Bruschi P, Ciani L, Clerici AM, Faraoni P, Ferrari C, Gadan MA, Panza L, Pietrangeli D, Ricciardi G, Ristori S: Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem 52: 7829–7835, 2009 – reference: 25) Miyatake S, Kawabata S, Hiramatsu R, Furuse M, Kuroiwa T, Suzuki M: Boron neutron capture therapy with bevacizumab may prolong the survival of recurrent malignant glioma patients: four cases. Radiat Oncol 9: 6, 2014 – reference: 60) Michiue H, Sakurai Y, Kondo N, Kitamatsu M, Bin F, Nakajima K, Hirota Y, Kawabata S, Nishiki T, Ohmori I, Tomizawa K, Miyatake S, Ono K, Matsui H: The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials 35: 3396–3405, 2014 – reference: 7) Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Välimäki P, Mäkitie A, Seppänen M, Minn H, Revitzer H, Kouri M, Kotiluoto P, Seren T, Auterinen I, Savolainen S, Joensuu H: Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys 82: e67–e75, 2012 – reference: 51) Hiramatsu R, Kawabata S, Miyatake S, Kuroiwa T, Easson MW, Vicente MG: Application of a novel boronated porphyrin (H2OCP) as a dual sensitizer for both PDT and BNCT. Lasers Surg Med 43: 52–58, 2011 – reference: 14) Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R: Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res 4: 1825–1832, 1998 – ident: 2 – ident: 3 doi: 10.1007/BF02699929 – ident: 1 doi: 10.1098/rspa.1932.0112 – ident: 59 doi: 10.1016/j.apradiso.2009.03.030 – ident: 16 – ident: 5 doi: 10.1093/brain/114.4.1609 – ident: 36 doi: 10.1016/j.radonc.2009.02.009 – ident: 19 doi: 10.3171/2013.5.JNS122204 – ident: 55 doi: 10.1158/1078-0432.CCR-06-0141 – ident: 31 doi: 10.1007/BF02699937 – ident: 39 doi: 10.1097/CCO.0b013e328356364d – ident: 20 doi: 10.1007/s11060-008-9699-x – ident: 58 doi: 10.1007/s11060-009-9945-x – ident: 42 doi: 10.1016/j.apradiso.2011.03.020 – ident: 6 doi: 10.1002/hed.20418 – ident: 34 doi: 10.1269/jrr.08043 – ident: 40 doi: 10.3171/jns.2006.105.6.898 – ident: 18 doi: 10.3171/jns.2005.103.6.1000 – ident: 4 doi: 10.1158/1078-0432.CCR-05-0035 – ident: 12 doi: 10.1021/cr941195u – ident: 30 doi: 10.1007/BF02699938 – ident: 9 doi: 10.1016/j.apradiso.2009.03.103 – ident: 52 doi: 10.1002/jps.24317 – ident: 53 doi: 10.1021/bc950077q – ident: 60 doi: 10.1016/j.biomaterials.2013.12.055 – ident: 46 doi: 10.1021/bc0501350 – ident: 32 doi: 10.1016/j.radonc.2006.04.015 – ident: 62 doi: 10.1007/s11060-008-9621-6 – ident: 61 – ident: 23 doi: 10.1016/j.ijrobp.2009.12.061 – ident: 47 doi: 10.2174/138955707780059808 – ident: 29 doi: 10.1093/jnci/85.9.704 – ident: 48 doi: 10.1007/s11060-008-9522-8 – ident: 41 doi: 10.1227/01.neu.0000279727.90650.24 – ident: 38 doi: 10.3171/jns.1997.86.5.0793 – ident: 10 – ident: 45 doi: 10.1021/jm900763b – ident: 11 doi: 10.1097/00005072-197204000-00005 – ident: 14 – ident: 27 doi: 10.1023/A:1005781517624 – ident: 54 doi: 10.1158/1535-7163.MCT-05-0161 – ident: 57 doi: 10.1158/1078-0432.CCR-07-1968 – ident: 7 doi: 10.1016/j.ijrobp.2010.09.057 – ident: 26 doi: 10.1093/neuonc/nov227.04 – ident: 25 doi: 10.1186/1748-717X-9-6 – ident: 50 doi: 10.2174/187152006776119135 – ident: 24 doi: 10.1093/neuonc/not020 – ident: 56 doi: 10.1158/1078-0432.CCR-06-2399 – ident: 21 doi: 10.1200/JCO.2006.08.1661 – ident: 22 doi: 10.1007/s11060-010-0333-3 – ident: 28 doi: 10.1016/S0360-3016(96)00241-6 – ident: 37 doi: 10.1016/0090-3019(86)90233-8 – ident: 35 doi: 10.1016/j.apradiso.2011.03.014 – ident: 49 doi: 10.1016/j.apradiso.2009.03.018 – ident: 13 doi: 10.1016/0360-3016(95)02180-9 – ident: 15 – ident: 8 doi: 10.1016/j.apradiso.2004.05.059 – ident: 33 doi: 10.1007/BF02699939 – ident: 44 doi: 10.1016/j.apradiso.2009.03.024 – ident: 17 doi: 10.1023/B:NEON.0000003751.67562.8e – ident: 51 doi: 10.1002/lsm.21026 – ident: 43 doi: 10.1016/j.apradiso.2014.01.011 |
| SSID | ssib002484387 ssj0037382 ssib002484385 ssib042166867 ssib058493722 ssib023157258 ssib058493721 ssib000959794 ssib023157257 ssib044754309 ssib058493723 |
| Score | 2.3980908 |
| SecondaryResourceType | review_article |
| Snippet | Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when... [Abstract] Boron neutron capture therapy [BNCT] is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when... |
| SourceID | pubmedcentral proquest pubmed crossref medicalonline jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 361 |
| SubjectTerms | Boron Neutron Capture Therapy Brain Neoplasms - diagnosis Brain Neoplasms - radiotherapy Brain Neoplasms - therapy glioblastoma high-grade meningioma Humans malignant glioma positron emission tomography Review |
| Title | Boron Neutron Capture Therapy for Malignant Brain Tumors |
| URI | https://www.jstage.jst.go.jp/article/nmc/56/7/56_ra.2015-0297/_article/-char/en http://mol.medicalonline.jp/en/journal/download?GoodsID=cd1neure/2016/005607/002&name=0361-0371e https://www.ncbi.nlm.nih.gov/pubmed/27250576 https://www.proquest.com/docview/1837343030 https://pubmed.ncbi.nlm.nih.gov/PMC4945594 |
| Volume | 56 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Neurologia medico-chirurgica, 2016, Vol.56(7), pp.361-371 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfK4ICEEIiPlY8pSFzQlC1OUjs5QVcNrUwdY0u1cbKS1Flb1qRqmwMc-D_4b3nPdkJaTQh2sZLYjhy_l_fh9_wzIW-zjk-dbOTYYepyG_7ExA48FtgyCX0uQ1Agan_F4IQdDf1Pl53LVutXI2upXCV76Y8b95XchqrwDOiKu2T_g7L1S-EBXAN9oQQKQ_lPND5A-AGQUyWuZ-_24rkKB0QaKEAlEA7AzL7CXBcgYjzJd6NyVpj4zbTCbSoXSgDGOs5e2Ol4sigXV40knkH_azfqHqvEyfPxJLf70KYW1d2L7gFUV5XTuuaofwYiPTofKjp-L-oew7PP_QvVISqW48l48q1orj7QzdUHtX8NtLr6VlDrenTXVcppQ5j53LED6ugIttTC1vND0JBmxcNIYw0zbriON0Srp0HbjZb29MEtmwoAHCxci8hn6d4CUaUobj_XCcANfpjPFEO4HO0_voHErXT76aDnhz54W_4dctcFDwQPxzj-0vTUAt8LOhv3ta-PeFEqgFV9to6Q4_D2NweHeNRmJGvG0b0p-AcI_PBgpmN2GjvlJldoM6O3YSJFj8hD49tYXc2oj0lL5k9IoJjUMkxqGSa1DJNawKRWzaSWYlJLM-lTMvx4GPWObHNch53ykK7shEnK4izJWErdlGfgSOMlTb3Mo5k7YmHC4pHfcVjCeMxCl3keDFgyGiQ0A0v2GdnKi1xuEwuMUCYzR47AIfATMKITeNUI7jIuHXhJm-xX8yRSg2WPR6pcC_BpcZIFTLJYxAInWeAkt8m7usdc47j8pe17PfV1S_OHq5YdJjgWzR51A9wqCZKpTT6s0UwYobEU6YgiUK3EvphQCg4HJoC4AixJKhA_E7eWsw4M4k1FZgESH8N4cS6LcilACXPPB9PTaZPnmuz1QCtGahO-xhB1A0STX6_JJ2OFKm_4_cWte74k9_9IiFdka7Uo5Wuw2FfJjlrp2lF_EJSDn4dQnpwOfgNKhuqi |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Boron+Neutron+Capture+Therapy+for+Malignant+Brain+Tumors&rft.jtitle=Neurologia+medico-chirurgica&rft.au=MIYATAKE%2C+Shin-Ichi&rft.au=KAWABATA%2C+Shinji&rft.au=HIRAMATSU%2C+Ryo&rft.au=KUROIWA%2C+Toshihiko&rft.date=2016-01-01&rft.pub=The+Japan+Neurosurgical+Society&rft.issn=0470-8105&rft.eissn=1349-8029&rft.volume=56&rft.issue=7&rft.spage=361&rft.epage=371&rft_id=info:doi/10.2176%2Fnmc.ra.2015-0297&rft_id=info%3Apmid%2F27250576&rft.externalDocID=PMC4945594 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0470-8105&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0470-8105&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0470-8105&client=summon |